Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Theranostic Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of SKL35501, an Alpha-Emitting Radiopharmaceutical Targeting NTSR1, With SKL35502 as Companion Imaging Agent in Adult Patients With Selected Advanced Solid Tumors

NCT07812805 is registered in ClinicalTrials.gov with SK Life Science, Inc. as lead sponsor.

NCT NCT07812805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07812805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Theranostic Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of SKL35501, an Alpha-Emitting Radiopharmaceutical Targeting NTSR1, With SKL35502 as Companion Imaging Agent in Adult Patients With Selected Advanced Solid Tumors
Lead sponsor
SK Life Science, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 19, 2026
Completion date
July 31, 2030
Enrollment
100 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer (btc), colorectal cancer (crc), esophageal cancer (ec), gastric cancer (gc), head and neck squamous cell cancer (hnscc), pancreatic ductal adenocarcinoma (pdac), selected advanced solid tumors